<a href="https://laohu8.com/S/DRMA">Dermata Therapeutics Inc</a>. Faces Nasdaq Delisting Risk Due to Non-Compliance with Minimum Bid Price Rule
Dermata Therapeutics Inc. has announced a regulatory issue concerning its compliance with Nasdaq's listing requirements. On May 14, 2025, the company received a notice from Nasdaq indicating that its common stock had fallen below the minimum bid price of $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). In response, Dermata is seeking shareholder approval for a reverse stock split at its upcoming annual meeting on July 15, 2025, as part of its efforts to regain compliance. Nasdaq has granted Dermata an exception until August 14, 2025, to meet the required bid price. Failure to do so, or to meet other listing requirements, could result in the delisting of Dermata's securities from the Nasdaq Capital Market.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-018042), on July 07, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.